Cimzia news from FierceBiotech
NewsUCB files for Cimzia RA approval in Europe
UCB is taking its case to make Cimzia the first PEGylated anti-TNF biologic available to rheumatoid arthritis patients in front of the European Medicines Agency. Recently approved for Crohn's, Cimzia Read more...
UCB CEO plots strategy following Cimzia approval
Fresh off the FDA's approval of Cimzia for Crohn's disease, UCB chief executive Roch Doliveux forecast a swift regulatory success in Europe. Cimzia is one of the most closely watched late-stage Read more...
EMEA shoots down UBC's Cimzia
It looks like UBC has struck out in the EU. The EMEA told the company that the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on Cimzia, a treatment for Crohn's Read more...
| Press ReleasesCimzia Approved in the US for the Treatment of Moderate to Severe Crohn's Disease Cimzia Approved in the US for the Treatment of Moderate to Severe Crohn's Disease Administered every four weeks, UCB's pegylated anti-TNFa offers new treatment option for patients with moderate to Read more... PRESS RELEASE: UCB Group Drug Cimzia Faces EU Delay, Shares Plunge UCB Group Drug Cimzia Faces EU Delay, Shares Plunge Brussels (BELGIUM), November 16, 2007 at 7:00 am CET - UCB announced today that it has been informed by the European Medicines Agency (EMEA) that Read more... |
Get more Cimzia coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets